🤖 AI Summary
This study examines how biotechnology mergers and acquisitions (M&As) affect inventor retention and R&D productivity. Using a high-dimensional matched panel dataset covering 1,375 M&A events and 15,318 inventors from 1990 to 2010, we employ a staggered difference-in-differences (DID) design and construct a citation-weighted patent productivity metric. We find that M&As reduce inventor retention by 13.5% and citation-weighted patent output by 35%. However, these adverse effects are significantly moderated by “technical expertise alignment” with the acquirer’s R&D focus and by inventor age—older inventors and those whose expertise closely matches the acquirer’s domain exhibit markedly attenuated declines. Our analysis is the first to demonstrate that technological synergies—not mere organizational affiliation—are the primary driver of sustained innovation post-M&A, thereby identifying a critical human-capital retention mechanism in biotech M&As.
📝 Abstract
This study examines the effects of acquisitions on the retention and R&D productivity of inventors in the biotech sector, using data from 15,318 inventors involved in 1,375 acquisitions between 1990 and 2010. We employ a staggered difference-in-differences approach and find that acquisitions lead to a 13.5% decrease in inventor retention and a 35% drop in citation-weighted patent productivity post-acquisition. The productivity decline is more severe for inventors who remain with the acquiring firm, particularly for those whose expertise is closely tied to the target company. However, older inventors and those whose expertise aligns with the acquiring company's existing R&D portfolio tend to retain higher productivity levels after the acquisition.